Australia appears to be welcome potentially transformative therapy for obesity: Retatrutide. This dual agonist – working on both GLP-1 and GIP receptors – demonstrates significant efficacy in clinical research, suggesting substantial decreases in body fat. While availability hasn't occurred with Australian regulators, several individuals strugg